(Yicai Global) May 30 -- A unit of US medical equipment giant GE Healthcare will work with a Chinese company to promote GE's breast cancer screening device Invenia ABUS, while aiming to set up at least one medical diagnostic center in each Chinese province in the next three years.

Shanghai-based GE Healthcare Trade Development agreed with Wanmatong Technology to create an ultrasound screening solution which will be suitable for public and private medical institutions, said the Hangzhou-based firm's parent in a statement, without disclosing details about the investment. 

Breast cancer is the most common cancer among women in China, and its rate has increased 3.5 percent from 2000-2013, according to data from China's national cancer registry. 

The pair's goal is to establish more than 30 remote reading diagnostic centers in major provinces throughout the country within three years. Wanmatong will establish a national training base in Hangzhou to provide reading services for these diagnostic centers. The firm will also develop 3D printing products applicable to GE's Voluson ultrasound device that is used for obstetrics and gynecology.

The Invenia ABUS is a non-ionizing alternative to other supplemental screening options, which can improve breast cancer detection by 55 percent over mammography, according to GE's website.

Editor: Emmi Laine